
Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026
Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology Cortigent is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind The Company is also developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysis due to stroke ALAMEDA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that Cortigent, Inc. (“Cortigent”), its wholly-owned subsidiary developing brain implant devices, presented the results of a 6-year Early Feasibility Study of the Orion® Visual Cortical Prosthesis System under development to deliver meaningful visual perception to blind persons at the North American Neuromodulation Society (“NANS”) annual meeting.


















